Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Peanut Oral Immunotherapy Study
NCT03251508Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jan 2018
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in peanut allergy, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percentage of Participants Experiencing Treatment-emergent Adverse Events During the 2-stage Study Sequence at 12 months. Started Jan 2018; status: completed.
02
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03251508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251508.